Debiopharm Group and Yale University announce a worldwide license agreement concerning the development and commercialization of Debio 1036, a first-in-class inhibitor for autoimmune and inflammatory diseases.

“We are very excited about this new collaboration with Yale. Their leadership in marrying chemistry and biology to identify and validate lead drug candidates has yielded a new approach to treating inflammatory disease. The Debio 1036 project aims at developing inhibitors targeting a fundamental inflammatory pathway, which plays essential roles in myriad diseases progression and severity,” said Rolland-Yves Mauvernay, PhD, president and founder of Debiopharm S.A.

Release Date: May 4, 2011
Source: Debiopharm Group